Stability of BPC-157 in solution: what has been measured — one year on posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
The answer changed when I changed how I was measuring, which was informative.
Post #60 answers the question as asked. The question underneath it is different.
I would keep Stability of BPC-157 and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
I read post #62 twice before replying, because I had assumed the opposite.
Stability of BPC-157 looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Building on post #64 rather than restating it.
Solubility in this family is generally good, which means a vial that will not go into solution readily is telling you something about the material rather than about the technique.
I would be interested in a counterexample if anyone has one.
Having read the whole Stability of BPC-157 thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Everything in post #66 holds. The case it does not cover is the one I have.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
Picking up post #68: that is the part I would want checked first.
What I would tell a new member reading about Stability of BPC-157 for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
On post #66 — agreed on the reasoning, with one qualification.
Adding a null result on Stability of BPC-157. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
This is the sort of thing the wiki should carry and currently does not.
Post #69 is the version of this I will quote in future. One addition.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
This is the sort of thing that ought to be settled and apparently is not.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
The confident answers on Stability of BPC-157 and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
That is the practical version. The rigorous version is longer and says the same thing.
Answering the question post #73 raises rather than the one it answers.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Happy to be corrected if someone holds better data than mine.
Post #77 and I disagree about the size of the effect, not about the direction.
Stability of BPC-157 is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
I have kept the units in throughout, for the obvious reason.
An honest declaration on Stability of BPC-157: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Reading rather than contributing, but this is the most useful thread I have found on it.
Confirming post #84 from a second method, which matters more than confirming it from a second person.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
I had written a reply contradicting post #84 and deleted it. Here is what survived.
Storage after reconstitution is where most of the practical questions land. Refrigeration, minimal temperature cycling, protection from light, and using it inside the period the supplier's stability statement covers.
The general answer and the answer for your case may diverge here.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.